AMD

This page shows the latest AMD news and features for those working in and with pharma, biotech and healthcare.

Novartis sees demand returning to pre-COVID-19 levels in Q2 results

growth of heart failure drug Entresto (sacubitril and valsartan), monoclonal antibody Cosentyx (secukinumab), gene therapy Zolgensma (onasemnogene abeparvovec), wet AMD therapy Lucentis (ranibizumab) and multiple sclerosis drug Kesimpta (ofatumumab).

Latest news

CHMP recommends eight new medicines for EU approval

Byoovis is designed for the treatment of wet age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema, proliferative diabetic retinopathy, visual impairment due to macular oedema secondary to
Novartis and smartpatient launch app experience for wet AMD patients

Novartis and smartpatient have launched a new educational app experience for patients with age-related wet macular degeneration (AMD). ... In the future, Novartis and smartpatient also plan to roll the wet AMD section out to further markets. .
Novartis stumbles in Q2 as COVID-19 impacts sales

That includes its wet AMD drug Lucentis (ranibizumab), which fell 25% to bring in $401m in the quarter.
Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD

Beovu (brolucizumab) is the first anti-VEGF treatment to demonstrate superior resolution of retinal fluid compared to Eylea (aflibercept) in patients with wet age-related macular degeneration (AMD), according to Novartis. ... aflibercept) squaring off
Novartis highlights emerging assets and late-stage pipeline at R&D day

It also has plans to expand wet AMD therapy Beovu(brolucizumab-dbll) and HER-2 breast cancer treatments Piqray (alpelisib) and Kisqali(ribociclib) into additional indications to help drive growth.

More from news
Approximately 26 fully matching, plus 78 partially matching documents found.

Latest Intelligence

25 Women Leaders in UK Healthcare (part 2)

for advanced dry Age-related Macular Degeneration (AMD).
Deal Watch October 2018

RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry Age-related Macular Degeneration (AMD). ... Effectively the deal is structured as an option, as the phase 2 study in dry AMD will be
30 Women Leaders in UK Healthcare (part 2)

treatments for age-related macular degeneration (AMD).
The good, the bad and the ugly

In the EU, where there’s a high prevalence of AMD, Bayer has enjoyed great success with Eylea - growing revenues by 18% in 2017,” says Alice Stevens, analyst, cardiovascular and metabolic ... The company plans to launch the highly anticipated
Working with our healthcare system more closely is vital

to essential treatment, expanding and improving care for people living with a leading cause of vision loss – age-related macular degeneration (AMD).

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

Gyroscope Therapeutics appoints CEO

Gyroscope has a unique translational approach to tackling complex diseases such as dry AMD for which there are no therapies today.”.